Korean oncology firms are gearing up for the American Society of Clinical Oncology (ASCO) meeting, showcasing a diverse range of clinical data and AI biomarker studies aimed at enhancing their global presence in oncology.
Scheduled for May 29 to June 2, 2026, in Chicago, ASCO 2026 will host a variety of stakeholders, including oncologists and investors. Korean companies plan to present findings across several cancer types, including immuno-oncology and targeted therapies, reflecting a shift towards more advanced clinical data and biomarker-guided strategies. Despite a challenging investment climate, these firms view ASCO as a pivotal opportunity for forging international partnerships and advancing their research.
Notable presentations include TiumBio's interim phase 2 data on its drug combination for head and neck cancer, showing promising response rates. HLB will discuss its liver cancer treatments, while STCube will present data on its immunotherapy candidate for colorectal cancer. Other companies like GI Innovation and Onconic Therapeutics will also share early clinical results, indicating significant potential for their therapies.
The integration of AI in biomarker studies is particularly noteworthy, with Lunit showcasing its AI-driven platform to identify patients who may benefit from specific treatments. This convergence of AI and clinical data highlights the innovative approaches being taken by Korean firms to address complex oncology challenges, underscoring the evolving landscape of cancer treatment.